XML Print

Department of Biochemistry, Faculty of Basic Sciences. University of Guilan, Rasht, Iran , aghamaali@guilan.ac.ir
Abstract:   (810 Views)
Background & Aims:  Alpelisib and Ursolic acid are two compounds that have been shown to have potential as anti-cancer agents. Alpelisib is a selective inhibitor of the PI3K pathway, while Ursolic acid is a natural pentacyclic triterpene compound found in various plants that reveals anti-cancer, antioxidant and anti-inflammatory characteristics. The hypoxia-inducible factor 1α (HIF1α) is a transcription factor that plays a key role in regulating tumor cell survival, apoptosis, tumorigenesis and growth in low-oxygen environments. This study aims to determine the effects of Ursolic acid and Alpelisib on the expression of HIF1α gene on 4T1 cell line.
Materials & Methods:  In the current experimental study, IC50 concentrations of both Ursolic acid and Alpelisib were determined on 4T1 cells. Then cells were treated with determined IC50 concentrations of Ursolic acid, Alpelisib and the combination of half of the IC50 concentration of both drugs for 24 hours. After the treatment, viability was assessed with MTT assay and the expression of HIF1α gene was appraised by Real-time PCR. Finally, statistical analysis was accomplished by ANOVA using GraphPad Prism 8.4 software.
Results:  The results of this study showed that the anti-proliferative effect of the drug combination was synergistic and concentration-dependent. The maximum decrease (74.17 % with UA and 64.04 % with Alp) in viability was observed in high doses of treatment with drugs. IC50 values of Ursolic acid and Alpelisib were 168.314 µM and 6.377 µM, respectively. Based on the real-time PCR results, HIF1α gene expression was significantly decreased in both single- treatment and combination groups, compared to the control group (P<0.05).
Conclusion:  The results of this study showed that both Alpelisib and Ursolic acid alone or in combination with each other could have anti-cancer effects by reducing HIF1α gene expression. Further studies are needed to determine the efficacy and safety of these compounds in vivo.
Full-Text [PDF 303 kb]   (264 Downloads) |   |   Full-Text (HTML)  (242 Views)  
Type of Study: orginal article | Subject: Other

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. lancet oncol 2001;2(3):133-40. [DOI:10.1016/S1470-2045(00)00254-0] [PMID]
2. Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res 2014;16(4):1-9. [DOI:10.1186/s13058-014-0427-5] [PMID] []
3. Favaro E, Lord S, Harris AL, Buffa FM. Gene expression and hypoxia in breast cancer. Genome Med 2011;3:1-12. [DOI:10.1186/gm271] [PMID] []
4. Corcoran SE, O'Neill LA. HIF1α and metabolic reprogramming in inflammation. J Clin Investig 2016;126(10):3699-707. https://doi.org/10.1172/JCI84431 [DOI:10.1172/jci84431] [PMID] []
5. Li H, Prever L, Hirsch E, Gulluni F. Targeting PI3K/AKT/mTOR signaling pathway in breast cancer. Cancers 2021;13(14):3517. [DOI:10.3390/cancers13143517] [PMID] []
6. Chang D-Y, Ma W-L, Lu Y-S. Role of Alpelisib in the treatment of PIK3CA-mutated breast Cancer: patient selection and clinical perspectives. Ther Clin. Risk Manag 2021:193-207. https://doi.org/10.2147/TCRM.S251668 [DOI:10.2147/tcrm.s251668] [PMID] []
7. Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, Bishayee A. Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. Biochem. Pharmacol 2013;85(11):1579-87. [DOI:10.1016/j.bcp.2013.03.006] [PMID]
8. Kashyap D, Tuli HS, Sharma AK. Ursolic acid (UA): A metabolite with promising therapeutic potential. Life Sci 2016;146:201-13. [DOI:10.1016/j.lfs.2016.01.017] [PMID]
9. Semenza G. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 2009;15(33):3839-43. [DOI:10.2174/138161209789649402] [PMID]
10. Goda N, Dozier SJ, Johnson RS. HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antioxid Redox Signal 2003;5(4):467-73. [DOI:10.1089/152308603768295212] [PMID]
11. Choi YH, Jin GY, Li LC, Yan GH. Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/HIF-1 alpha/VEGF pathway. PLoS One 2013;8(11):e81773. [DOI:10.1371/journal.pone.0081773] [PMID] []
12. Iqbal J, Abbasi BA, Ahmad R, Mahmood T, Kanwal S, Ali B, et al. Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications. Biomed Pharmacother 2018;108:752-6. [DOI:10.1016/j.biopha.2018.09.096] [PMID]
13. Shan J, Xuan Y, Zhang Q, Zhu C, Liu Z, Zhang S. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer. Protein Cell 2016;7(8):571-85. [DOI:10.1007/s13238-016-0295-0] [PMID] []
14. Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 2020;11(9):797. [DOI:10.1038/s41419-020-02998-6] [PMID] []
15. Book: Kumar AP, et al. Complementary and Alternative Medicines in Prostate Cancer. A Comprehensive Approach. 1 th ed. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2016:93-110. [Google Scholar]
16. Kassi E, Sourlingas T, Spiliotaki M, Papoutsi Z, Pratsinis H, Aligiannis N, et al. Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells. Cancer Invest 2009;27(7):723-33. [DOI:10.1080/07357900802672712] [PMID]
17. Gómez Tejeda Zañudo J, Mao P, Alcon C, Kowalski K, Johnson GN, Xu G, et al. Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations. Cancer Res 2021;81(17):4603-17. https://doi.org/10.1158/0008-5472.CAN-21-1208 [DOI:10.1158/0008-5472.can-21-1208] [PMID] []
18. Shan J-z, Xuan Y-y, Zheng S, Dong Q, Zhang S-z. Ursolic acid inhibits proliferation and induces apoptosis of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway. J Zhejiang Univ Sci B 2009;10:668-74. https://doi.org/10.1631/jzus.B0920149 [DOI:10.1631/jzus.b0920149] [PMID] []
19. Shan J-z, Xuan Y-y, Zhang Q, Huang J-j. Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1α. J Zhejiang Univ Sci B 2016;17(9):672. https://doi.org/10.1631/jzus.B1600266 [DOI:10.1631/jzus.b1600266] [PMID] []

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.